142035-33-4Relevant articles and documents
Mitotic kinesin inhibitors
-
Page/Page column 32, (2010/11/25)
The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Highly enantioselective synthesis of β-amino alcohols
Metro, Thomas-Xavier,Appenzeller, Jerome,Pardo, Domingo Gomez,Cossy, Janine
, p. 3509 - 3512 (2007/10/03)
N,N-Dialkyl-β-amino alcohols derived from α-amino acids can be rearranged enantiospecifically by using TFAA/Et3N/NaOH to give 1,2-amino alcohols with enantiomeric excess up to 99%.
Synthesis of methylamino-2-phenyl-2-butyl-3,4,5-trimethoxybenzoate, the main bioactive metabolite of trimebutine maleate
Martin, Arnaud,Figadere, Bruno,Saivin, Sylvie,Houin, Georges,Chomard, Jean Marie,Cahiez, Gerard
, p. 544 - 549 (2007/10/03)
The first synthesis of the methylamino-2-phenyl-2-butyl-3,4,5- trimethoxybenzoate (desmethyltrimebutine) I is described. This compound is the main bioactive metabolite of trimebutine II (Debridat, CAS 39133-31-8), an antispasmodic widely used for intestinal diseases since 1969. It was used for pharmacokinetic and bioequivalence studies.